Please login to the form below

BCMA

This page shows the latest BCMA news and features for those working in and with pharma, biotech and healthcare.

BMS and 2seventy bio move away from CAR-T programme

This cancellation is the second anti-BCMA CAR-T programme to be halted under BMS in the last twelve months, after a development programme with Juno Therapeutics was scrapped in February ... Abecma, approved in March 2021 as the first BCMA CAR-T programme,

Latest news

bluebird bio splits to create new oncology firm 2seventy bio

Its portfolio includes a development and commercialisation deal with Bristol Myers Squibb for Abecma (idecabtagene vicleucel), its B-cell maturation antigen (BCMA)-directed CAR T-cell therapy approved by the Food
EC approves BMS cell therapy for multiple myeloma

The European Commission (EC) has approved Bristol Myers Squibb/bluebird bio’s first-in-class anti-B-cell maturation antigen (BCMA) CAR T cell therapy Abecma (idecabtagene vicleucel) for patients with ... Abecma is the first CAR T cell therapy that is
FDA grants orphan drug status to Allogene’s BCMA-targeted treatment for multiple myeloma

ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies. ... Phase 1 data from the ALLO-715 UNIVERSAL trial demonstrated for the first time that
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

In June, AbbVie exercised a right to acquire TeneoOne – a Teneobio affiliate – which includes adding an anti-CD3/BCMA bispecific TNB-383B candidate for the treatment of relapsed or refractory multiple
FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

The investigational B-cell maturation antigen (BCMA) CAR T therapy, also known as cilta-cel, is backed by results from the phase 1b/2 CARTITUDE-1 study.

More from news
Approximately 7 fully matching, plus 55 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... BCMA to which Celgene already has access.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Highlights in haematologic malignancy from ASH 2018

Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.